RespireRx Pharmaceuticals Inc (CE) (RSPI) News

Ok thanks … do you have any links or info re how you know that some insiders are taking this approach of “back end payoffs.” TIA

I think some speculation around that time was the DoD news was shorting as there was huge amount of volume over two days…

Right before EM that was surely sell off by short term traders not wanting to hold long.

I believe majority of shares are in actual retail who are true investors and larger interest who probably have better ideas how things will transpire. Insiders all own huge equity linked interests..

Ya Menace, I was talking about the 100s of millions that were sold just prior to them leaving the OTC for the EM. Cheers

The events that have happened in EM are not consolidation. Just shakey shares being sweeped up at various ranges. Single party swap no MM involved here. Just inpatient shares slipping to new investors who are trying to increase their stash at ridiculously low prices. If we come out of EM even with not so good deal newes we still should pump to 01 minimum. Just from all our patents and a progress report on that dod trial. That's almost 10x from current levels

Hey LT … can you again (sorry) outline why you think the mass volume days after the DOD grant announcement and then the week before the fall to the EM were consolidation events and not a sell off by major shareholders before that happened. Appreciate you.

Thank you.  I'm trying to learn about this stuff.  Hopefully this can be my home run hitter like ILUS was for me 

Who knows, being on EM, they are acting like they are private entity anyhow. Other companies with this type of pipeline/positioning generally secure VC capital and they have talked about moving assets to the LLC and getting EndeavourRX funding, so assumption is that is in the works. Assuming also HEAL efforts and NIH support to submit IND and phase 1 plans is maturing as well. The other one is status of epilepsy grant. Would think they know by now. Maybe they did not get it, or either they have to refine details to secure it?

With all the above and details from shareholder letter it is hard to understand why the filings and off EM is not completed by now given key items closing in on completion.. so maybe there is merger and acquisition activity slowing this down..

Agree with you on that , and that maybe while nothing has been updated for shareholders due to a or many NDAs in place. If they came out and said we have NDAs in place that would make many shareholders happy I believe. IMO

Yes, a Non-Disclosure Agreement (NDA) can affect subsidiaries, but it depends on how the NDA is written and the specific relationship between the parent company and its subsidiaries. If the NDA explicitly includes subsidiaries or affiliated entities, then they are bound by the agreement's terms. However, if the NDA only names the parent company, it may not automatically extend to subsidiaries, especially if they are not explicitly mentioned.
Here's a more detailed breakdown:
Explicit inclusion:
If an NDA defines the obligated party as the parent company "and its affiliates" or specifically lists the subsidiary, then that subsidiary is indeed bound by the NDA.
Implicit inclusion:
Even without explicit mention, some NDAs may imply coverage of subsidiaries if the definition of "disclosing party" or "receiving party" is broad enough to encompass them.
Independent subsidiaries:
If a subsidiary operates independently and has no direct interaction with the confidential information covered by the NDA, then it might not be bound, even if it's under the same parent company.
Need for individual agreements:
If there's any doubt or if the subsidiary needs to access the confidential information, it's generally best to have a separate NDA with that specific subsidiary or amend the existing one to include them.
Parent company's responsibility:
Often, the NDA will hold the parent company (or the primary contracting party) legally responsible for any breaches of confidentiality by its subsidiaries or any other party it shares the information with.
Legal advice is crucial:
Due to the complexities of corporate structures and the nuances of NDA language, it's always advisable to consult with a legal professional to determine the exact scope of an NDA's applicability to subsidiaries.

Material events still need to be disclosed however. Define “material”…. Probably not until they submit an IND, or ink VC/BP deal.

If they get grant funding it could be grey area as to when they need to announce. They could wait until they begin drawing down or such I suppose. Could be subject to NDA.

What if asset is considered to be part of subsidiary EndeavourRX?

If you are asking do I think if it gives a pass , I would say no . They have said more than some companies on the EM not by much. Now as far as what they are legally required is really nothing.

Companies trading on the Expert Market, a tier of the OTC Markets Group, are not required to provide regular public disclosures like those on other OTC tiers (e.g., OTCQX, OTCQB) or major exchanges.
Key Points about Expert Market Disclosure:
No Mandatory Reporting: Unlike other public markets, companies on the Expert Market have minimal to no disclosure obligations.
Limited Information: This lack of required reporting means investors have very little information available about Expert Market companies.
Restricted Access: Trading on the Expert Market is primarily limited to broker-dealers, institutions, and other sophisticated investors, not the general public.
Why are Companies on the Expert Market?
Companies may end up on the Expert Market due to:
Failure to meet disclosure requirements of other OTC tiers.
Lack of financial information or regulatory compliance.
SEC Rule 15c2-11 enforcement actions for not providing current and publicly available information.
Consequences of Expert Market Listing:
Limited Trading: Trading is restricted to sophisticated investors.
Reduced Liquidity: Lack of public information and access makes trading difficult and illiquid.
Increased Risk: The limited information and trading restrictions make Expert Market securities highly speculative and risky.
In summary, companies on the Expert Market do not have mandatory reporting requirements. Investors should be aware of the significant risks and limitations associated with these securities due to the lack of available information.

Does being on the EM give them a pass on these updates to their shareholders?

Maybe all the EM was so they didnt need to inform until the time was right

The only thing I can add to this discussion is that the thesis that reported the results of a preclinical evaluation of CX929 where the author reported that he couldn't publish in a peer-reviewed journal until 2026, (The thesis is no longer available) This suggests not only that access to the CX929 was restricted by a Non-Disclosure Agreement, but also a plan by RSPI is in place in which they believe will come to fruition by 2026. I suspect RSPI forced the online removal of that thesis.

I don’t know. Seems like the lines become very blurry between NDA, material event disclosure and confidentiality. And how much of this is required to be disclosed in SEC quarterly filings..

They are still a publicly traded company…. Barely by being on this EM.

Could be , depending if they are picking up the rest of the bill after the grants money is gone . Who really knows what they are working on and with who

Looking at their paths or potential irons in the fire…

-tier 3 NIH HEAL for 18 months is intended I believe to come out of this with IND submission and phase 1 plans. Huge since the program is opioid mitigation.

-KRM-ll-81 Grant funding for epilepsy IND enabling. They should know where they stand in this regards I would think. But could a NDA hide this or do they need more work to secure?

-phase 2 SCI with DOD funds. All hurdles ready to cross?

-Additional ampakine grant filings? The submit or close to ? Multiple more grant applications?

- OSA been dormant even with committed funding.. Schedule 3 getting close in USA, has this been stalled reason?

Additional collaborations for other indications making progress? GRIA, anxiety, orphan?

No reason to be trading for peanuts on EM, so much potential here…

It just seems like this path forces all other asset development to a halt. And they still could be building out interest, so by choosing not to suggests they have all the money interest they need sitting at the round table..

I am certain all involved know time is money and opportunity can be lost to competitors for all asset paths Respire owns… the risk they choose on this path!

So when they emerge I expect full on game plans to surface and multiple candidates heading into clinical trials and additional candidates going deeper into preclinical or IND enabling. Transformation.

I would think for certain there would be multiple NDA’s in place as they negotiate….

However, would having NDA’s in place cover them from having to disclose material events related to say grant funding or NIH HEAL progress?

It could depending on what actually has been written into the NDA by the parties involved. This might be why Jeff is vague at times with his answers,

A Non-Disclosure Agreement (NDA), also known as a confidentiality agreement, is a legal contract outlining confidential information that parties wish to share with each other but restrict access to. It establishes a confidential relationship between parties, where one or more agree not to disclose certain information to unauthorized parties. NDAs are crucial for protecting sensitive business information and intellectual property in various situations.
Key aspects of an NDA:
Confidential Information:
NDAs define what information is considered confidential, which can include trade secrets, business strategies, financial data, customer lists, and more.
Parties Involved:
NDAs specify who is bound by the agreement, including the disclosing party (who owns the confidential information) and the receiving party (who agrees to keep it confidential).
Obligations:
The receiving party is typically obligated to maintain the confidentiality of the information, limit its use to authorized purposes, and not disclose it to third parties without permission.
Term and Termination:
NDAs can have a defined term (e.g., one to five years) or be indefinite. The agreement may also specify conditions for termination.
Consequences of Breach:
Violating an NDA can result in legal action, including lawsuits for damages and potentially associated legal costs.
Common uses of NDAs:
Business Negotiations:
.
Sharing sensitive information during mergers, acquisitions, or partnerships.
Employee and Contractor Agreements:
.
Protecting company information shared with employees, contractors, and freelancers.
Research and Development:
.
Safeguarding intellectual property and inventions during the development process.
Product Development:
.
Protecting confidential information about new products or services.
Consulting Agreements:
.
Allowing consultants to access sensitive information while maintaining confidentiality.
Types of NDAs:
Unilateral NDA:
.
Only one party discloses confidential information, and only the other party agrees to keep it confidential.
Bilateral (or Mutual) NDA:
.
Both parties disclose confidential information and agree to keep each other's information confidential.
Multilateral NDA:
.
More than two parties are involved, and they all agree to maintain confidentiality.
Enforcement:
NDAs are generally enforceable in court, but the terms of the agreement must be clear, reasonable, and not overly broad, according to some legal resources. In California, for example, courts may refuse to enforce NDAs that are too vague or broad.

If they were in some sort of NDA, would that not preclude them from releasing results of their studies, like they have I believe , as a said company would have tied them up? Layman’s curiosity here.

My thoughts are blowwn at this point , the what when and why have confused all of us, just sitting back at this point and seeing where the ride takes us. It has been a year so what is a few more weeks , month or years the money we invested here is pretty locked up for now. I think it will be worth while the question is when at this point. GLTA

Thanks for the feedback. I still find it strange or odd that they are then still on this EM. Don't you?

If they are closing in on strategic deals. Whether large scale VC funding or they have locked in major grant funding or a BP partnership/cash-milestones agreement.... Given the timeline of things in motion, why haven't they acquired small funding/loan to move the SEC filings to completion and off this EM market BEFORE all those things come to fruition?? This is why it is starting to feel like something different may be in store.. than simply returning to the OTC. Could be a reverse merger with another entity/listed company, could be a buyout of certain programs, but somethings must be in motion where having retail and larger investing interests with access to acquiring positions of common shares is not that big of a concern. At all.

Maybe they spin out EndeavourRx and certain assets into an entirely new entity, thus distributing equity of newco to existing common shareholders and other stakeholders?

I guess the other possibility is they just want to announce the huge news or series of news while still on the EM! This will restrict access for most retail and other investor interests while also allowing institutional and accredited investors to absorb the float on the way up! Also controlling price spikes. Common retail investors like this forum usually like to drip off a few shares here and there as valuations rise.. So while on EM, large institutional level interests can absorb shares at 1-2-5-even ten pennies, acquire majority of float and then as they eventually trade on a higer exchange these entities could drive the prices much much higher while significant phase 1 and phase 2 and more clinical activity begins... Thoughts?

Any news that you can comment on or pass out as new news. You had said we would be getting an update awhile back. Just checking if any time frame in the horizon to pass along . Natives are getting restless to hear good news and direction and the end of being on the EM.
Thanks

They have a number of very newsworthy items in process, but it’s still premature to announce them. They are hoping for very soon, but they’re all on different schedules and hopefully all will come to fruition, but they can’t be sure until the actually happen, or don’t. That is a summarized of the reply

I wonder how they will drop the filings. Will they go 1-by-1 and drop a filing every few days or will it be a lump and they drop all filings they are missing over a single day or two. After the filings are all dropped, what is the time period to be current? I think bigT or someone mentioned 30 days... Any insight? Probably at minimum also need to see an 8K with whatever minor funding is agreed to that completes all the SEC paperwork and gets current.

Or will they drop huge VC or BP level related news and then complete the paperwork?

Feels like the smarter approach would be to glide off the EM first and allow shares to rise to a new level and consolidate, then start dropping grant funding, collaborations, huge VC funding, IND's, clinical trial initiations phase 1 and/or phase 2 and then BP partnerships, etc... A consistent and sustainable rise in price over say 3-6 months versus a 10000% rise over 3-6 days.... We'll see I suppose. GLTA.

Well done you! I hope this takes off soon. First, it would teach a good lesson about how the culture of development of pharmaceuticals is broken. Second, I could use some funds myself to buy, a house, maybe. Third, I think I might benefit myself from popping some Ampakines and Gabakines to relieve some cognitive and anxiety issues. I can see no downsides to it.

…yes have been accumulating over the last 6 months. Like the story and have some faith in the community here. Have been able to increase my holding by 5 milly over that period. Hoping this is the real deal. GLTE

I actually will not be surprised and more or less am expecting a big announcement in the future which could be next week or next year given the snails pace.

I think the due diligence of the science and their methodical approach positioning their candidates for best possible success heading into clinicals has been very solid. This bears out in the publications and connecting dots from similar competitor activities.

But I would guess most agree that this is a very unorthodox way to treat shareholders and present your company to the pharmaceutical and investing world and I have yet to hear any legitimate reason as to why.... I guess it is what it is. Very well might be the prettiest girl at the ball.... But if the carriage never arrives, nobody will ever know it.

Yeppers LT disappointing for sure until they surprise us(:

Yeah, the hunt is on for shares for sure. Were you able to add to your pile today with a little more volume than normal?

We'll see how they get back off the EM. I am guessing similar to other pharma stories that emerge from the shadows and launch into key clinical trials that there are both VC and BP lurking here and probably directing things since at this point the future into clinical trials is out of RSPI's wheelhouse. Maybe they will ink some preferred share investment first and slide off the EM with filings completed and maybe with some grant funding in their pocket while they are finalizing details of major investment from VC or directly into BP partnership too. Nickel-Dime-Quarter and more is a very plausible progression.

They shouldn't have to "promise" news. It has been 2 months since some on here were again saying news was coming....

Imagine if they just stayed current and sustained a more reasonable market valuation, even just 20 million and provided shareholders the CONFIDENCE that they were doing things on the up and up. It would be A LOT easier and less consternation amongst all stakeholders. All this EM path did was sew concern and distrust.

And if communication and presentatation of the company information on websites, etc was consistent and done with clarity and respect to all shareholders, they would be sitting pretty as they presumably are negotiating strategic deals to bring the resources in to launch their premier candidates into human clinical trials.

They would have the flexibility and leverage to reach out for additional collaborations, and build a broader base of interest and investors...

What could have been....

While we are waiting... AI has commentary:

According to Barron's, the average price target for RespireRx Pharmaceuticals Inc. (RSPI) is $975.00. However, the current price is significantly lower, fluctuating around $0.0007 per share. This suggests a vast difference between the analyst's estimation and the current trading price.
Comparing this to the estimates for other stocks, several factors emerge:
Significant Discrepancy: The difference between RSPI's current price and the $975.00 estimate is exceptionally large. For instance, the average stock price target for stocks in the S&P 500 is about 12% higher than the current stock price. In another example, the average price target for Varonis Systems (VRNS) represents a forecasted upside of 9.00% from its current price. The disparity with RSPI is drastically higher.
Accuracy of Price Targets: The accuracy of price targets in the long run is debatable, with studies showing mixed results, and some sources even calling them "mostly useless".
Factors Influencing Price Targets: Several factors can contribute to the wide variation in analyst price targets, including:
Differing Assumptions and Methodologies: Analysts use various valuation methods and may have different assumptions about future company performance and market conditions.
Changing Market Conditions: Dynamic market conditions can impact stock prices, and price targets, if not regularly updated, may not reflect these changes.
Focus on Short-Term Factors: Analysts may sometimes overemphasize short-term factors like quarterly earnings, potentially overlooking long-term prospects.
In conclusion, Barron's estimate of a $975.00 future stock price for RSPI stands in stark contrast to its current trading value. While analyst price targets can offer a perspective on a stock's potential, their accuracy is debated, and they are influenced by a range of factors that can lead to significant variations. Investors should consider multiple perspectives and conduct thorough research before making any investment decisions.

Right bigtalan, there has been no stated timeframe to get off EM,  only as you said, they are working on it, an update as promised would be nice

I havent seen anything in my emails about that , all he has stated was they were working on it and it would be as soon as they can. GLTA

Didn't Margolis say that RespireRX would emerge from EM in March, or was it April? Perhaps something has cropped up (hopefully good) that has caused this delay from emerging from EM?

Chomp chomp...got em before the new tariffs!

Yeah, there really has not been any meaningful volume for over a year now.

And by all indications the company has been in strategic negotiations for quite awhile which not only coincides with having advanced to toxicology/IND/phase 1 prep in the NIH HEAL pain program or having a phase 2 candidate trial pending with DOD funding or looking to initiate epilepsy indication/grant funding efforts... but also makes sense with all the activities listed in the shareholder letter and a long standing intent to "license, partner or sale" all of their candidates/assets.

We also know by dealings of companies like Saniona/Acadia, SiteOne Therapeutics, etc, we can infer what massive potential is pent up with KRM-ll-81 being a premier candidate for BOTH pain indications and epilepsy indications.

The recent weeks and months of very odd, very small share lots to me indicates a stirring and hunt for shares as I have seen this activity in the past. Whether this is "probing" or market maker signals or whathaveyou, I am sure there is venture capital lurking here. And the set-up or potential with such a deep pipeline of premier candidates rivals the most storied pharma stocks that have been mentioned. While my opinion is that this EM trip is a very wasteful approach and I would prefer to see price adjustments happen on a consistent incline over many many moons, if what happens next is simply a familiar pharma story of 50-100-200x price adjustment, then I suppose we would all be for that as well. GLTA.

Looks like everyone is just sitting back and waiting on what is next. Stay cool and safe depending on the weather in your area. GLTA

One of the best examples of what is possible is the pharma BrightMinds, ticker DRUG on the Nasdaq. It hovered around a 7-10 million market cap. Out of the Blue, there was news and major funding that reset the valuation in less than a week. I believe it peaked around 500 million market valuation settling yet today around 200 million valuation.

Fortunes can and will literally turn on a DIME.

That one from yesterday , it ran to 7.13 and then ended 4.38 today. Hang in folks I think and have said it before RSPI can have such a run when trading and the right news is dropped at the right time. GLTA

PROK
ProKidney Corporation
4.38
0.65 (17.43%)
Volume: 209,456,882
Day Range: 4.18 - 7.13
Bid: 4.37
Ask: 4.39
Last Trade Time: 6:16:10 PM EDT
Total Trades: 1,226,519

Did any of the ones here that can trade try buying and selling a set amount as suggested in a previous post. I see a whooppping 50 shares sold today.

Yeah, that is what these forums are intended for to help improve participants understanding of the potential. Also serves as group therapy. lol

I am guessing we are pretty close. Tier 3 HEAL (noted 18 months ago) into toxicology and intended IND submission and phase 1 has to be getting close to movement based upon typical timelines. They should have an idea of grant funding incoming and additional opportunities and the phase 2 SCI has been sitting out there over a year now, so "overcoming hurdles" should be in-process. With everything mentioned as well as items from shareholde letter all getting compressed on the time line, once they lock in funding, there is likely to be a constant and continual stream of PR and updates for months on end....

I just hope this EM path is not costing them/us massive opportunities and opening the door to the competition. It is a very embarrassing and hard to fathom look that needs to be reconciled.

ALL is good , we both are throwing out views that could happen , and I know we all want to see this moving positive in nature. I think with what they have told us , the amount of money they have not taking from the company but instead took options based on success we will have something worth while to look forward too. Maybe the holdup is getting the books squared away for whatever is coming next, any company would want to see what they are getting into bed with, or as others would say what is actually under the hood. I would say that VC, BP all have seen and heard about RSPI pipeline, but most likely want to be 1000% sure that nothing from the past will come back to bite them. Every stone will be looked at and looked at again. IMO

AS for thoses forecast prediction they all make me laugh when posted. Walletinvestor and others come out with some crazy numbers at time. Walletinvestor is showing a .15 in a year , now that one I can believe, but I have seen them put some crazy forecast out too. Its a nice dream for us , but will it happen 99.99999999 it wont .Boy if it did we all will be buying islands to live on.

GLTA

Maybe I am extrapolating to much the potential reasons they went EM by suggesting reverse merger and just getting trading again on the OTC will indeed be the first step.

At this point one would have to assume the announcements will come while still "trading" on the EM. Your chicken and egg comment makes sense. They cannot complete the filings and SEC work until they have funding in place so if VC and grant level funding is announced first, likely SEC filings, paperwork and the much acclaimed website updates will be secondary. This would create a huge rise in the stock price, but with limitations of being on the EM maybe keep it reigned in somewhat (i.e. not hitting $975 just yet! LOL)

Could easily see a nickel or two initially on the EM and any consolidation can be absorbed by institutional level investors. AFTER exiting EM, then I suppose there could be bigger news in the works, like initiating that phase 2 SCI or grant funding activities or IND application and phase 1 initiation coming out of HEAL with maybe all if it culminating in a big BP partnership or license agreement with cash and milestones which would be more than appropriate in this situation. Then maybe we see a quarter or two.... prolly not $975 though...

Otherwise, I am not sure how they exit the EM. I could imagine a total buyout of the neuromodulators could be on the table. Give the shareholders 10 or 20 pennies and then allow the bigger money to reap the bigger rewards as they move these candidates through clinical trials... with all this dragging on so long now, they might just be putting together 1 larger "sail into the sunset" type deal.

If they are doing the ( manufacture of the ampakines ) it is being over seen by others who know what they are doing. AKA look at how many colleges are doing studies with their compound. If they are doing what they are saying I would say they are not worried about a website at this point , that will come in time .Or as you are stating a merger of some sort then I say they would worry about the website ect..
Money and contacts are the key things they are focused on at the moment I would think

AI Overview
RespireRx Pharmaceuticals Inc. is involved in the development of AMPAkines, which are a class of proprietary compounds that act as positive allosteric modulators of the AMPA glutamate receptor. While the information does not explicitly name a specific manufacturing partner for their AMPAkines, it indicates a collaborative approach:
RespireRx is developing these compounds through its EndeavourRx business unit.
They have engaged in research collaborations, notably with University College London to study the use of AMPAkines for treating GRIA disorders.
Dr. David Fuller, a collaborator from the University of Florida, has conducted studies on the ability of RespireRx's lead AMPAkines (CX1739 and CX717) to improve motor nerve activity and muscle function in models of spinal cord injury.
Therefore, while a specific manufacturing entity is not named, it appears RespireRx is relying on its internal research and development capabilities, as well as academic collaborations, to develop their AMPAkine compounds.

who is helping manufacture of the ampakines for respirerx company
RespireRx Pharmaceuticals Inc. has established research collaborations for the development of its AMPAkines, particularly CX1739 and CX717.
University of Florida: Dr. David Fuller at the University of Florida is a long-time collaborator with RespireRx. His research has focused on the ability of CX1739 and CX717 to improve motor nerve activity and muscle function in animal models of spinal cord injury (SCI).
University College London (UCL): RespireRx has a collaboration with UCL to study AMPAkines for the treatment of GRIA disorders. Dr. Ian Coombs is leading efforts to identify specific genetic variants in children with GRIA Disorder to personalize treatments.
However, the provided search results do not explicitly mention a specific manufacturing partner for RespireRx's AMPAkines. There is a mention of AbbVie Contract Manufacturing being listed as a company profile in a news article related to RespireRx, but it's not definitively stated as the manufacturer. ResolutionRx Ltd., a subsidiary of RespireRx, has partnered with Ab Initio Pharma Pty Ltd for the manufacturing and testing of their dronabinol lipid nanoparticle formulation. However, this partnership is focused on dronabinol, not the AMPAkines.
AI responses may include mistakes.

Ampakines, positive allosteric modulators of the AMPA glutamate receptor, are being investigated for various therapeutic uses. The manufacturing process for ampakines involves several complex chemical synthesis steps and techniques to produce them at a larger scale.
Here are some insights into the manufacturing process of ampakines:
Regioselective reactions: Ampakine synthesis often involves regioselective reactions to ensure the formation of the desired isomer. For example, a regioselective CDI-mediated amidation process has been optimized for coupling amines with a terephthalic acid substrate.
Multi-step synthesis: The synthesis often requires multiple steps, including nitration, oxidation, and reduction reactions, each requiring careful control of reagents, temperature, and reaction conditions. For example, one synthesis involves a regioselective nitration using nitric acid and sulfuric acid.
Scale-up and optimization: Developing and manufacturing an ampakine-type active pharmaceutical ingredient for clinical trials requires careful consideration of scale-up issues, safety calorimetry, and optimization of each step for large-scale production, potentially in multikilogram quantities.
Quality control: Chromatography on silica gel may be required to purify crude products and achieve satisfactory chemical purity.
Catalytic reactions: Some ampakines can be synthesized using catalytic domino reactions, such as cobalt-catalyzed hydroformylation of dihydrooxazines, which offers an efficient route to these heterocycles.
It's important to note that the specific manufacturing process can vary depending on the particular ampakine compound being produced. Companies like RespireRx are actively involved in the development and potentially the manufacturing of ampakines, according to SEC.gov. Other companies may also be involved in the research and development, and potentially, manufacturing of ampakines.
In summary, the manufacture of ampakines is a sophisticated chemical process involving a series of steps that need careful optimization for large-scale production, adhering to pharmaceutical standards and regulations.

Sounds complex. So for a company who cannot manage a simple website nor SEC compliance, is there any reason to believe they could or should manage manufacturing or any clinical trials for that matter?

License, partner, sale.... Simply put this has to happen next.

This is the search I entered ( manufacture of the ampakines) as you can see I did not list a company at all. anyone can try the same and see what it gives you .
Based on the search results, the manufacture of ampakines involves several steps, including:
Synthesis: Ampakines are typically synthesized through a series of chemical reactions. For example, one described method involves a regioselective nitration step using nitric and sulfuric acids, followed by other steps like methylation, oxidation, coupling, and reduction to obtain the final ampakine compound. Another approach describes a cobalt-catalyzed hydroformylation of dihydrooxazines to produce compounds like CX-614.
Process Development: Before large-scale manufacturing, the synthesis process is developed and optimized to ensure efficiency, safety, and scalability. This involves optimizing each step, addressing scale-up issues, and conducting safety calorimetry.
Manufacture: Once the process is developed, the ampakine active pharmaceutical ingredient (API) can be manufactured on a larger scale. This often involves CDI-mediated amidation for coupling amines with a terephthalic acid substrate.
Companies involved in the manufacture of ampakines include:
RespireRx Pharmaceuticals: RespireRx develops ampakines and holds patents for most medical uses of these drugs. This company is working to advance compounds like CX1739, CX717, and CX1942 through clinical trials.
Cortex Pharmaceuticals: Cortex Pharmaceuticals developed earlier ampakines such as CX-546, CX-516, and CX-614. Biovail acquired certain ampakine compounds, including related intellectual property, from Cortex Pharmaceuticals in 2010.
Servier: Servier, in collaboration with Cortex Pharmaceuticals, advanced the ampakine compound S47445 (CX1632) into Phase I clinical studies.
Note: The search results mention that several companies manufacture or are involved in the development of amphetamines. Ampakines are a separate class of compounds with a different mechanism of action and intended therapeutic uses, even though they also target glutamate receptors like amphetamines.
Therapeutic Potential and Challenges:
Ampakines may be useful in treating neurological disorders by improving glutamate transmission in the brain. However, some "high-impact" ampakines have shown calcium-dependent neuronal toxicity, which has limited their development as drugs. Research has identified differences between high-impact and "low-impact" ampakines, with the latter having a better safety profile and a wider therapeutic window. Companies like RespireRx are focusing on developing these low-impact ampakines for conditions such as opioid-induced respiratory depression and spinal cord injury.

Well I agree that they have the candidates and stellar preclinical/clinical science. Plenty of peer reviewed publications and competitor comparative activities confirm this!

I agree with Neutrino though in that they have not indicated any desire to run a large pharmaceutical company. They have consistently indicated: "license, partner or sale" of all their assets. They do not have the resources in terms of clinical trial experience, manufacturing, distribution, etc, etc. This is why clinical ready candidates are most often partnered with BP or similar to advance. Surely this is what the makeup is of these strategic dealings they have been mentioning about for over a year.

Whether or not this is a pseudo "IPO" does not matter much. Pharmas of all types on the OTC or higher exchanges like that NASDAQ have had the tendancy to stay dormant until the deals are ready to fund and push into phase 1/2/3 clinicals. Suddenly valuations are often reset to the tune of 20x, 50x, 100x or even more! I expect something similar here unless they completely fumble this fabulous opportunity and positioning of assets.

I think what is upsetting to all stakeholders is this path to the EM. Purposely allowing your company to be valued for peanuts or a fraction of estimated NAV is embarrassing. And it continues for over a year as activities supposedly are maturing! Does this provide ANY leverage in strategic dealings? Does this make the NIH or other organizations less willing to provide your company grants or enter key collaborations? Does lacking in professional communication and presentation benefit stakeholders and the quest to enter these assets into clinical trials with multiple candidates?

Assuming that negotiations and discussions are being led by more experienced parties and some of this is out of their control..... Then why are you wasting time not building out your communications or presentations, building your base of interest for not just investment but collaboration? Why are they still on this EM market?

I'm a science guy, and don't really understand the nuances of the market. Given that, I believe RSPI is intending the equivalence of an IPO. They sure have the molecules and patents to do so. Looks to me that one of the reasons for staying so long in EM was to get their patents updated for especially the ampakines - I suspect oral administration on their lead molecules is a biggie. And then there is the manufacture of the ampakines - do they hold the patents or pending? AI couldn't find, but I believe they do (based on a publication earlier this year).
RespireRX is not aiming for partnerships, but a re- IPO and counting on irrational exuberance to jack the stock price up so high that they will easily finance their own clinical trials.

If I had to speculate, which is the nature of speculative stocks, especially ones that divert attention away from themselves and remain stagnant in communication and presentation.

It is only logical BP has been watching KRM-ll-81 and maybe even encouraged entry into HEAL program. Insider bias to accumulate equity positions began at that point. Confidence. Progressing to tier 3 IND enabling is huge step and requires BP level resources. Assumption dealings along this line is in the works. Capturing VC capital and support is key for the rest of the story/candidates. It would make sense for multiple strategic deals to be maturing sooner than later. Time is money! But these assets and position heading into clinicals need institutional level support, hence why they prolly don’t care about EM, OTC, and all that jazz.